The Peptide Lugdunin isolated three years ago produces bacteria Staphylococcus lugdunensis, which is on the human mucosa of the nose. Lugdunin has a special chemical structure and could be a prototype of a new class of antibiotics. These are cyclic peptides incorporating a characteristic ring-ring compound of thiazolidine sulfur nitrogen. This thiazolidine ring provides an antibacterial effect.
Scientists from the University of Tübingen and Göttingen and the German Center for Infection Research investigated the isolated peptide and deciphered a mechanism of action that differs from previous antibiotics. As a result, bacterial energy supply is disturbed and they die. Because of this particular mechanism of action, the peptide should also be effective against multi-resistant germs.
In order to test the resistance development of Lugdun, the team produced various derivatives, so-called. Fibupeptide. Gradually, they changed parts of the chemical structure and each determined antibiotic activity. It was found that there was no difference in the effect between the starting molecule and its mirror image. Researchers have been able to prove that efficiency is not based on spatial interaction, which hampers rapid development of resistance.